Introduction
============

Vulvar cancer is a malignant invasive lesion occurring in the vaginal opening, the labia majora (the most common site), the labia minora and the clitoris. Vulvar cancer accounts for 0.6% of all cancer diagnoses and 5% of gynecologic cancers.^[@bib1],\ [@bib2]^ Vulvar cancer is typically a squamous cell carcinoma (SCC) that is also common in other gynecologic organs, including the cervix and vagina.^[@bib1],\ [@bib2]^ Whereas almost all cervical SCCs occur with the background of human papillomavirus (HPV) infection,^[@bib3],\ [@bib4]^ vulvar SCCs consist of those associated with HPV as well as others independent of HPV infection.^[@bib1],\ [@bib2]^ Both HPV (+) and HPV (−) vulvar SCCs are preceded by vulvar intraepithelial neoplasia (VIN).^[@bib5],\ [@bib6]^ These two types of vulvar SCCs along with their precursors exhibit different epidemiological, pathological, clinical and molecular features.^[@bib1],\ [@bib2],\ [@bib5],\ [@bib6]^ Approximately one-third of all vulvar SCC patients suffer from recurrence, for which therapeutic options are limited.^[@bib7]^

SCCs developed in female genital tracts share common features, including HPV infection and the progression of squamous intraepithelial neoplasia to invasive SCCs.^[@bib3],\ [@bib4]^ Like cervical intraepithelial neoplasia, VINs progress to SCCs but the progression rates are lower than those of cervical lesions,^[@bib5],\ [@bib6]^ indicating that the pathogenesis of cervical and vulvar SCCs may differ in part.

With the improvement of next-generation sequencing (NGS) technology, comprehensive molecular profiles of many cancers have been studied using NGS,^[@bib8]^ which allows for the investigation of thousands of variants within a given tumor sample.^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^ Using a targeted sequencing approach for 14 genes, a recent study identified that most HPV-negative (−) vulvar SCCs (83%) contained one or more somatic mutations in *TP53*, *CDKN2A*, *HRAS*, *KRAS*, *PIK3CA*, *PPP2R1A* and *PTEN*, with *TP53* being the most commonly mutated gene.^[@bib13]^ In contrast, HPV-positive (+) vulvar SCCs harbored a *TP53* mutation in 17% of cases but the remaining 83% were silent without any driver mutations.^[@bib13]^ Their study strongly suggests not only that HPV-dependent and HPV-independent vulvar SCCs may have different mutation profiles but also there could be hidden mutations not discovered by the targeted approach only for the 14 genes. Other studies using conventional gene-to-gene analyses have shown similar mutation data in vulvar SCCs.^[@bib1],\ [@bib2],\ [@bib14],\ [@bib15]^ Thus far, a number of studies have reported the mutational profiles of SCC in many organs (non-genital: head/neck, esophagus and skin; genital: uterine cervix and penis) using high-throughput genome profiling technologies.^[@bib11],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19]^ However, to date, the genomic data of vulvar SCCs at the whole-genome or whole-exome level is absent. Thus, it is necessary to examine the mutational profiles of vulvar SCCs in addition to the well-known gene mutations, including *TP53*. In this study, we analyzed the genomes of 15 vulvar SCCs using NGS-based whole-exome sequencing (WES) to identify the mutational profiles of vulvar SCCs.

Materials and methods
=====================

Vulvar cancer tissues
---------------------

Vulvar SCC tissues resected by surgery were obtained from 15 Korean patients. Tissues from one patient were frozen (VSCC2) and those from the other 14 patients were formalin-fixed paraffin-embedded (FFPE). This study was approved by the Institutional Review Board (IRB) at The Catholic University of Korea, College of Medicine. Clinicopathologic characteristics of the 15 vulvar SCC patients are summarized in [Table 1](#tbl1){ref-type="table"}. Both frozen and FFPE tissues were cut and examined under a microscope by two pathologists. Tumor and normal cells were selectively procured from hematoxylin-stained sections by microdissection. The purity of the tumor cells from the microdissection was approximately 70%. HPV (+) tumors were determined using real-time polymerase chain reaction (PCR) for HPV obtained from a commercial company for molecular diagnosis (Seegene, Inc., Seoul, Korea).

WES and somatic mutations
-------------------------

WES was performed on the genomic DNA obtained from tumor and matched normal tissues using the Agilent SureSelect Human All Exome V4 Kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's instructions. WES data were processed as previously described.^[@bib20]^ Briefly, the paired-end sequencing raw data (FASTQ format) were aligned to the human reference genome (hg19) using Burrows--Wheeler aligner software (BWA, v0.7.15).^[@bib21]^ The Genome Analysis toolkit (GATK, v3.6),^[@bib22]^ Picard (<http://picard.sourceforge.net>; v2.7.1) and Samtools (v1.3.1)^[@bib23]^ were used for the basic processing and management of marking duplicates, including local realignments and score recalibration. Somatic mutations were detected by comparing tumor and matched normal sequencing data using MuTect^[@bib24]^ and SomaticIndelDetector^[@bib22]^ for point mutations and indels, respectively. ANNOVAR (Annotate Variation) was used for the functional annotation of each variant in the coding regions.^[@bib25]^ PolyPhen-2 was used to predict the impact of an amino-acid substitution on protein function and structure.^[@bib26]^ We validated 21 mutations of 9 genes using either digital PCR or Sanger sequencing. Putative regions of kataegis were identified in samples where mutations had an average inter-mutation distance of no more than 10 kb.^[@bib27]^

Comprehensive analysis of mutational signatures
-----------------------------------------------

Somatic mutation signatures were estimated using the SomaticSignatures R package,^[@bib28]^ in which a mutation spectrum was decomposed with a non-negative matrix factorization (NMF) algorithm. Mutational signature analyses were rerun 20 times to confirm the results and an optimal number of signatures was chosen based on the maximum differentiation between the signatures. To compare the mutation signatures of the 15 vulvar SCCs with other cancer types, we first calculated the similarities between the mutational signatures using 30 known signatures recorded in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (<http://cancer.sanger.ac.uk/cosmic/signatures>).^[@bib29]^ Similarities between mutational signatures were calculated using a cosine correlation similarity ranging from 0 and 1, where one represented identical signatures and zero represented completely non-identical signatures. Next, we systematically analyzed the mutational signatures of SCCs using data from The Cancer Genome Atlas (TCGA)^[@bib30]^ and a comprehensive literature review of NGS-based studies for SCCs.^[@bib11],\ [@bib16],\ [@bib31],\ [@bib32],\ [@bib33]^ Data were composed of four types of SCCs from TCGA (CESC: cervical squamous cell carcinoma, ESCA: esophageal squamous cell carcinoma, HNSC: head and neck squamous cell carcinoma, LUSC: lung squamous cell carcinoma)^[@bib30]^ and two SCCs from NGS-based studies (CSCC: skin cutaneous squamous cell carcinoma,^[@bib11],\ [@bib16]^ OSCC: oral squamous cell carcinoma^[@bib31],\ [@bib32],\ [@bib33]^).

DNA copy number and loss of heterozygosity analyses
---------------------------------------------------

Copy number alterations (CNAs) were defined for each of the 15 vulvar SCCs using the ngCGH module and RankSegmentation statistical algorithm in NEXUS software v7.5 (Biodiscovery, Inc., El Segundo, CA, USA).^[@bib34]^ Loss of heterozygosity (LOH) events were inferred using Sequenza.^[@bib35]^ Identified CNAs and LOH events were manually curated based on the depth ratio and B allele frequency.

Results
=======

The catalog of somatic mutations
--------------------------------

A total of 15 vulvar SCC genomes (6 HPV (+) and 9 HPV (−)) and paired normal tissue genomes were analyzed in this study ([Table 1](#tbl1){ref-type="table"}). The coverage of the sequencing depth was a median of 141.8X (90.6--171.4X) for SCCs and 130.0X (60.6--180.7X) for paired normal tissues ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). A total of 2084 nonsilent (27--297/per tumor; median of 130) and 924 silent mutations were identified in the vulvar SCC genomes with a mean rate of 5.6 somatic mutations per megabase ([Figure 1a and b](#fig1){ref-type="fig"}, [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). These rates are higher than those of CESC (3.0 per megabase), ESCA (2.8), HNSC (3.3) and OSCC (2.6), but lower than those of CSCC (12.5) and LUSC (7.4). In terms of the sequence characteristics of point mutations, the C\>T substitution was the most common type (31.0% 56.8% at CpG and 43.2% at non-CpG contexts) ([Figure 1b](#fig1){ref-type="fig"}). The frequencies of somatic nonsilent mutations in HPV (−) SCCs (average of 175 per tumor) were significantly higher than those of HPV (+) SCCs (average of 84.8 per tumor) (*P*=0.03). The base substitutions were mainly C\>T or C\>G and did not differ between HPV (+) and HPV (−) SCCs. Comparison data between HPV (+) and HPV (−) SCCs are summarized in [Table 2](#tbl2){ref-type="table"}.

Cancer-related genes
--------------------

Cancer-related genes were extracted from the Cancer Gene Census (<http://cancer.sanger.ac.uk/census>)^[@bib36]^ and genes previously reported in vulvar SCCs.^[@bib1],\ [@bib2],\ [@bib5],\ [@bib13],\ [@bib14],\ [@bib15]^ We identified a total of 56 cancer-related genes that contained not only known vulvar SCC mutations (*TP53*, *CDKN2A*, *PIK3CA* and *HRAS*) but also previously unknown vulvar SCC mutations, including *APC*, *FBXW7*, *BRCA2*, *RB1* and *FAT1* ([Figure 2a](#fig2){ref-type="fig"}). The putative driver mutations showed significantly higher mutation allele frequencies (mean MAFs; 0.19) than the other mutations (mean MAFs: 0.16, *P*=0.02). The PolyPhen-2 analysis^[@bib26]^ revealed that the majority of the putative driver mutations (34 of 56, 61%) were predicted to have damaging effects on protein function ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

Recurrent nonsilent mutations (⩾2 cases) were found in 21 genes, including *TP53* (5 cases), *APC* (3 cases), *KMT2C* (3 cases) and *PIK3CA* (2 cases) ([Figure 2a](#fig2){ref-type="fig"}). The number of driver mutations in HPV (−) SCCs (average of 10.6 per tumor) was significantly higher than that of HPV (+) SCCs (average of 2.8 per tumor) (*P*=0.0002). However, 4 of 6 HPV (+) SCCs still harbored one of the known driver gene mutations (*PIK3CA*, *BRCA2* and *FBXW7*) ([Table 2](#tbl2){ref-type="table"}). There were more non-synonymous mutations in HPV (−) SCCs (average of 6.8 per tumor) than HPV (+) SCCs (average of 1.5 per tumor) and *TP53* was the most frequently mutated gene in the vulvar SCC genomes ([Figure 2a](#fig2){ref-type="fig"}).

Six truncating mutations were identified in known tumor suppressor genes (TSGs) *FAT1*, *BRCA2*, *CASP8* and *SMAD2*. Of note, *FAT1* harbored nonsilent mutations in 3 SCCs: VSCC15 with a nonsense mutation (p.W4175X), VSCC13 with 2 different nonsense mutations (p.S3268X and p.Q1455X) and VSCC9 with a missense mutation (p.D3749N). Three of six truncating mutations were identified in the *FAT1* gene (p.W4175X, p.S3268X and p.Q1455X), which were located in known functional domains (cadherin domains and the intracytoplasmic domain) ([Figure 2b](#fig2){ref-type="fig"}).

Mutation signatures
-------------------

We analyzed signatures of the somatic mutations detected in the vulvar SCCs using the NMF algorithm ([Figure 3a and b](#fig3){ref-type="fig"} and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) and found that C:G\>T:A transitions, which are frequently observed in mutations with oxidative DNA damage,^[@bib37]^ were predominant in the vulvar SCCs. A decomposition of mutation spectra using the NMF algorithm revealed a pattern similar to signatures 1 and 2 in the COSMIC database ([Figure 3c](#fig3){ref-type="fig"}). Signature 1 (S1) is related to endogenous mutational processes present in most cancers and signature 2 (S2) is characterized by over-activity of the APOBEC cytidine deaminases. Three SCCs (VSCC3, 7 and 9) and another 3 (VSCC4, 14 and 15) SCCs dominantly exhibited S1 and S2, respectively. In terms of HPV status, there was no clear difference in the mutational signatures between HPV (+) and HPV (−) SCCs. However, the C\>T transition, in the context of TpCpG trinucleotides, was more abundant in HPV (−) SCCs (average contribution of 0.17 per tumor) than in HPV (+) SCCs (average contribution of 0.14 per tumor). The contribution of the C\>T transition in the context of TpCpA trinucleotides was similar regardless of HPV status. When compared with other SCCs, cervical SCC showed the most similar mutation signature pattern (APOBEC family of cytidine deaminases) to the signature from the vulvar SCCs ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

CNAs and LOH
------------

By analyzing the WES data, a total of 590 CNAs (334 gains and 256 losses) were identified in 13 vulvar SCCs ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). Two vulvar SCCs (VSCC9 and 15) were not included due to low qualities, which were measured by data noise level (quality score of 0.157 and 0.099 for VSCC9 and 15, respectively). No significant difference in the number or length of CNAs was observed between HPV (+) and HPV (−) genomes (*P*=0.53 and 0.75, respectively) ([Table 2](#tbl2){ref-type="table"}). In the HPV (+) SCCs, we found 15 recurrently altered CNA regions, where a gain on 3q25.33-q29 was the most recurrent event (83%) ([Table 3](#tbl3){ref-type="table"}). With regards to the HPV (−) SCCs, we found 18 recurrently altered CNA regions, where gains on 7p and 8q and a loss on 2q (all 57%) were the most recurrent CNAs ([Table 3](#tbl3){ref-type="table"}). The CNA profiles were largely compatible with previously identified CNAs in vulvar SCCs ([Table 3](#tbl3){ref-type="table"}).^[@bib38]^ In earlier studies,^[@bib38]^ an 8q gain (86%) and an 11q loss (29%) were the most common CNAs in HPV (−) vulvar SCCs. In the present study, 13q, 18p-q, 20p, and 20q gains were newly discovered in the HPV (+) SCCs ([Table 3](#tbl3){ref-type="table"}). In the HPV (−) SCCs, gains at 7p, 10q, 14q and 21p-q and losses at 2p and Xp-q were newly discovered ([Table 3](#tbl3){ref-type="table"}). Cancer-related genes such as *FOXL2*, *PIK3CA*, *TP63*, *SOX2*, *TERT*, *BCL2*, *SMAD2* and *GNAS* in the regions of gains, as well as *BIRC3* in the region of loss, were detected in the SCCs ([Table 3](#tbl3){ref-type="table"}, [Figure 4a and b](#fig4){ref-type="fig"}).

Importantly, 4 of 6 HPV (+) cases (VSCC1-4) showed copy gains at the *PIK3CA* locus (3q26.32). Two of them (VSCC1 and 4) harbored a hotspot missense mutation (p.E545K) ([Figure 4c](#fig4){ref-type="fig"}). The MAF of the missense mutation at the *PIK3CA* copy gain locus was 49% and the mean MAF in the copy-number neutral region was 24% in VSCC4. Similarly, in VSCC1, the MAF of the mutation in the *PIK3CA* copy gain locus was 21% and the mean MAF in the copy-number neutral region was 17%. Although further experimental validation is required, these data suggest that these two events may have occurred in the same allele. Two of 7 HPV (−) SCCs also exhibited copy gains at the *PIK3CA* locus.

Next, we assessed the B-allele profiles of the 13 vulvar SCCs and identified 6 copy-neutral LOH events (2q33.1-q37.3, 3q11.2-q29, 7p22.3-p11.2, 7q22.1-q36.3, 9q22.2-q34.3 and 17p13.3-p11.2) in 4 (31%) cases (1 HPV (+) and 3 HPV (−)) where important cancer-related genes are located, including *TP53*, *PIK3CA*, *NOTCH1*, *CASP8*, *EGFR*, *BRAF*, *FOXL2* and *TP63* ([Figure 5](#fig5){ref-type="fig"}).

Localized hypermutation
-----------------------

Two vulvar SCCs with HPV (+) had a recurrent region of kataegis (a focus of localized substitution hypermutations) at chromosome 16p12.3-q22.2 (chr16:19 566 736--72 137 834) ([Figure 6](#fig6){ref-type="fig"}). The mutations in kataegis are usually characterized by clusters of C\>T and/or C\>G in the text of TpC dinucleotides.^[@bib39]^ In agreement, we observed that most mutations in the kataegis region involved Tp[C]{.ul}pN mutations, with an inter-mutational distance of no more than 10 kb ([Figure 6](#fig6){ref-type="fig"}).^[@bib27]^ Of note, the kataegis region in our study co-localized with the copy gain of the *DHX38* gene, which is involved in RNA splicing.

Discussion
==========

Although the mutational landscape of cervical SCCs is already known,^[@bib9]^ that of vulvar SCCs is unknown. The aim of this study was two-fold. First, we attempted to disclose somatic mutations and CNAs of vulvar SCCs genome-wide. Second, we attempted to disclose genomic differences between HPV (+) and HPV (−) vulvar SCCs. We found that the vulvar SCCs harbored not only known mutations in driver genes such as *TP53*, *PIK3CA* and *HRAS* but also novel mutations in cancer-related genes such as *APC*, *FBXW7*, *BRCA2*, *RB1* and *FAT1*. We also found mounting evidence that HPV (+) and HPV (−) SCCs may differ with respect to genetic alterations, some of which were previously unknown. For example, the *TP53* mutation was known as a sole driver mutation in HPV (+) vulvar SCCs^[@bib13]^ but other driver gene mutations (*PIK3CA*, *BRCA2* and *FBXW7*) were detected in the HPV (+) SCCs in the present study.

Most recurrent CNAs of HPV (+) SCCs in the present study were largely in agreement with those described in earlier studies, while those of HPV (−) were not, except for the gain on 8q.^[@bib15]^ Of note, the gain on 3q was the most recurrent CNA in the HPV (+) vulvar SCCs, while the gains on 7p and 8q and the loss on 2q were the most recurrent in HPV (−) cases. Unlike somatic mutations that exhibited higher frequency in HPV (−) SCCs than in HPV (+) SCCs, the CNA frequencies between HPV (−) and HPV (+) vulvar SCC genomes did not differ. Together, our data suggest that a 3q gain where *PIK3CA* is located plays a role in vulvar SCC development irrespective of the HPV status and that the other CNAs could be related to HPV status. In the 5 SCCs (2 HPV (+) and 3 HPV (−)), we found a copy-neutral LOH, also called uniparental disomy (UPD), in which there are two copies of a chromosome from one parent and no copies from the other parent due to errors in meiosis I or meiosis II.^[@bib40]^ The copy-neutral LOH may contribute to the development of tumors that are homozygous for preexisting mutations.^[@bib41]^ The copy-neutral LOH areas in the vulvar SCCs identified in this study harbored tumor suppressor genes (*TP53* and *CASP8*) and an oncogene (*PIK3CA*). We are the first to report this copy-neutral LOH in vulvar SCCs; however, its distribution as well as its biological and clinical significance in vulvar SCCs remains to be clarified.

Diverse endogenous and exogenous mutational processes leave distinct patterns of mutational signatures embedded within cancer genomes.^[@bib42]^ Signature 1, initiated by the deamination of 5-methyl-cytosine, is found in the majority of human cancers^[@bib43]^ and has a probable association with aging.^[@bib42]^ Signature 2 is the second most common signature related to the APOBEC family of cytidine deaminases coupled with DNA replication and repair machineries.^[@bib39],\ [@bib44]^ The co-occurrence of these two signatures is found in SCCs from the cervix, head/neck and esophagus.^[@bib42]^ The vulvar SCCs examined in this study had both signatures 1 and 2 without any other distinct signatures. These data suggest that vulvar SCCs may not harbor any other distinct mutational etiologies such as alcohol, tobacco and ultraviolet exposure besides HPV and aging.

In two HPV (+) SCCs, we found recurrent kataegis, a process related to the activation of APOBEC enzymes, at 16p12.3-16q22.2 on the basis of substitution type and sequence context of cytosine mutations.^[@bib39],\ [@bib42]^ Currently, kataegis is not defined by a statistics-based analysis; therefore, although our observation of a kataegis-enriched mutation is in agreement with a previous report,^[@bib39]^ a proper statistical method for such purposes should be developed. APOBEC activity is induced in HPV-infected cells and is highly associated with HPV (+) head/neck cancer.^[@bib45]^ The 16q22.2 locus (with the kataegis) encompasses the *DHX38* gene that encodes an RNA helicase and is involved in RNA splicing.^[@bib46]^ Whether the recurrent kataegis involving *DHX38* is specific for the tumorigenesis of vulvar SCCs remains to be studied in a larger cohort.

The most common mutation identified in this study was the *TP53* mutation (5/15), consistent with previous studies.^[@bib5]^ The *TP53* mutation in one case (VSCC8) was accompanied by a *TP53* copy loss, which would result in the complete inactivation of *TP53*. Six vulvar SCCs showed *PIK3CA* copy gains. Of them, 2 cases (VSCC1 and 4) harbored concurrent *PIK3CA* mutations, while the other 4 cases harbored only *PIK3CA* copy gains without any *PIK3CA* mutation. When combining the *PIK3CA* mutations with the copy gains, *PIK3CA* genetic alterations in vulvar SCCs reached 60%, suggesting that it may be the major genetic alteration in vulvar SCCs. Further experimental validation of the concurrent *PIK3CA* alteration and its biological roles will be required. Additionally, 3 HPV (−) SCCs harbored nonsense or missense mutations of the tumor suppressor gene *FAT1*, while the other 3 HPV (−) SCCs harbored *FAT1* copy losses. All of these events occurred in HPV (−) SCCs, suggesting that an alteration in *FAT1* would be an HPV (−) SCC-specific event, although the sample scale was not sufficient to conclude this hypothesis. Recurrent somatic mutations of *FAT1* have been reported in multiple human cancers, including head/neck SCC, cervical adenocarcinoma and glioblastoma;^[@bib47]^ they reported truncating mutations (p.R146M, p.W543X and p.E314X) in the cadherin and cytoplasmic domains of the *FAT1* gene, the same locations as those reported in our study.^[@bib47]^ In addition, *FAT1* inactivation by somatic mutations activates Wnt signaling and promotes tumorigenesis.^[@bib47]^ HPV (−) head/neck SCCs harbor frequent *FAT1* mutations with loss of functions, which are significantly associated with better overall survival in HPV (−) patients but not in HPV (+) patients.^[@bib48]^ Based on our data, the clinical significance of *FAT1* inactivation in vulvar SCCs should be further examined in future studies.

Vulvar SCC has been divided into two different etiologic pathways (HPV-associated and HPV-non-associated). However, the genetic differences between these two have not been studied by genome-wide analyses. Based on the present study, the following conclusions were made: (i) the overall loads for somatic mutations (total mutations, nonsilent mutations and driver mutations) are higher in HPV (−) SCCs than in HPV (+) SCCs; (ii) the overall loads for CNAs (length and number) are not different; and (iii) the profiles of driver mutations and CNAs overlap but are not identical ([Table 2](#tbl2){ref-type="table"}). Several HPV-induced genes such as E6 and E7 act as oncogenes that promote tumor growth and malignant transformation, which could render HPV-infected cells less independent of additional somatic mutations for cancer development than HPV-uninfected cells.^[@bib49],\ [@bib50]^ Because there was no difference in the overall CNA loads, it can be hypothesized that HPV status may not have substantial effects during SCC development. The overlapping but different profiles of driver mutations and CNAs between HPV (+) and HPV (−) SCCs suggest that vulvar SCC development may require genetic alterations specific to either HPV-dependent or HPV-independent lesions in addition to common genetic alterations of HPV-dependent and HPV-independent SCCs.

In summary, we report the global genomic alteration profiles of vulvar SCCs to provide a better understanding of both the HPV-dependent and HPV-independent pathogenesis of vulvar SCCs. The genomic features of vulvar SCCs identified in the current study aid in a better understanding of the etiology of vulvar SCCs.
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![Compositions of somatic mutations identified in vulvar cancer genomes. (**a**) Mutation frequency in vulvar cancer genomes compared with those in other squamous cell carcinomas (CESC, cervical squamous cell carcinoma; CSCC, skin cutaneous squamous cell carcinoma; ESCA, esophageal squamous cell carcinoma; HNSC, head and neck squamous cell carcinoma; LUSC, lung squamous cell carcinoma; OSCC, oral squamous cell carcinoma; Mb, megabase). The median mutation frequency value is indicated next to each bar. Numbers of cases for each squamous cell carcinoma are shown in parentheses. (**b**) Number of somatic mutations (upper plot) and type of base pair substitution (lower plot) of 15 vulvar SCC genomes (6 HPV (+) and 9 HPV (−)) are shown. A total of 2084 nonsilent and 924 silent mutations were identified in 15 vulvar SCC genomes.](emm2017265f1){#fig1}

![Putative driver mutations identified in vulvar SCCs. (**a**) Cancer-related genes listed in the Cancer Gene Census (<http://cancer.sanger.ac.uk/census>) identified in this study are shown for each sample. Fractions of each mutation in the SCCs are shown in the left plot. (**b**) Schematic representation of FAT1 protein domains and predicted locations of the mutations detected in vulvar SCCs. Black dot, truncating mutation; Green dot, missense mutation.](emm2017265f2){#fig2}

![Mutation signatures of vulvar cancers. (**a**) The contribution of each signature to the filtered somatic mutation burden for each SCC. HPV status is shown in black (HPV (+)) and gray (HPV (−)). (**b**) Mutations within a trinucleotide context split by each of the two signatures generated from the NMF algorithm. (**c**) Each plot shows similarities between the mutational signatures from vulvar cancers and 30 known mutation signatures from the COSMIC database. Bars with high similarities are colored in red (cosine similarity ⩾0.8).](emm2017265f3){#fig3}

![Copy number alterations identified in HPV (+) vulvar SCCs. (**a**) Genome-wide frequency of copy number alterations in HPV (+) SCCs. Gain (positive axis, red). Loss (negative axis, blue). (**b**) Genome-wide frequency of copy number alterations in HPV (−) SCCs. (**c**) Focal amplification at the *PIK3CA* gene locus (3q26.32, red arrows) identified in four HPV (+) SCCs. Green arrows indicate *PIK3CA* missense mutations (p.E545K) in VSCC1 and 4.](emm2017265f4){#fig4}

![Copy-neutral loss of heterozygosity (LOH) events identified in vulvar cancers. (**a**) Copy-neutral LOH events at cancer-related gene loci are highlighted with red square boxes. The upper bar represents the B allele frequency (0.0--0.5) and the lower bar represents the depth ratio (0.0--2.5). (**b**) List of copy-neutral LOH events identified in vulvar cancers. Four vulvar SCCs with copy-neutral LOH at cancer-related gene loci.](emm2017265f5){#fig5}

![Kataegis identified in vulvar cancers. Regional hypermutation plots in two cancers. Upper panels of **a** and **b**: the left plot represents an individual sample in which each dot represents a single somatic mutation colored on a chromosomal basis. The right plot represents the same data colored by mutation type. Mutations are ordered consecutively on the *x* axis from the first mutation in the short arm of chromosome 1 to the last mutation in the long arm of chromosome X. Kataegis at chromosome 16 is highlighted by a red square box. Lower panels of **a** and **b**: kataegis loci are shown on chromosome 16.](emm2017265f6){#fig6}

###### Clinicopathologic features of vulvar cancers

  *Sample*   *Age (years)*   *Tumor size in diameter (cm)*      *Diagnosis*     *Extent of carcinoma*   *HPV infection (high- and low-risk types)*   *Sample source*
  ---------- --------------- ------------------------------- ----------------- ----------------------- -------------------------------------------- -----------------
  VSCC1      60              3.5                                 Vulva SCC          Microinvasion                     \+ (HPV16, −)                       FFPE
  VSCC2      74              3                                   Vulva SCC        invasion (7.0 mm)                   \+ (HPV16, −)                      Frozen
  VSCC3      78              3                                   Vulva SCC        Invasion (8.0 mm)                   \+ (HPV58, −)                       FFPE
  VSCC4      61              0.5                                 Vulva SCC          Microinvasion                     \+ (HPV16, −)                       FFPE
  VSCC5      66              2                                   Vulva SCC        Invasion (6.0 mm)                   \+ (HPV52, −)                       FFPE
  VSCC6      47              1.5                                 Vulva SCC        Invasion (1.0 mm)                   \+ (HPV16, −)                       FFPE
  VSCC7      70              2.5                                 Vulva SCC        Invasion (7.0 mm)                        ---                            FFPE
  VSCC8      70              4                                   Vulva SCC        Invasion (4.0 mm)                        ---                            FFPE
  VSCC9      45              1.3                              Vulva SCC (VIN)        No invasion                           ---                            FFPE
  VSCC10     61              0.6                                 Vulva SCC        Invasion (1.4 mm)                        ---                            FFPE
  VSCC11     62              2.4                                 Vulva SCC        Invasion (1.0 mm)                        ---                            FFPE
  VSCC12     69              4                                   Vulva SCC        Invasion (7.0 mm)                        ---                            FFPE
  VSCC13     79              4                                   Vulva SCC        Invasion (1.0 mm)                        ---                            FFPE
  VSCC14     64              1.7                              Vulva (VIN) SCC        No invasion                           ---                            FFPE
  VSCC15     83              1.2                                 Vulva SCC        Invasion (4.0 mm)                        ---                            FFPE

Abbreviations: FFPE, formalin-fixed paraffin-embedded; HPV, human papilloma virus; VIN, vulva intraepithelial neoplasm.

HPV infection risk types are indicated in parentheses (high risk, low risk).

High-risk HPVs are indicated by the numbers 16, 52, and 58.

###### Summary of comparison data between HPV (+) and HPV (−) vulvar cancer genomes

                                                   *HPV (+)*                                    *HPV (−)*                          P*-value*
  --------------------------------------- ---------------------------- ----------------------------------------------------------- -----------
  Somatic mutation number                         116.8/tumor                                  256.3/tumor                         0.03
  Mutation allele frequency                       0.23/variant                                0.15/variant                         \<0.001
  Nonsilent mutation number                        84.8/tumor                                   175/tumor                          0.03
  Mutation allele frequency (nonsilent)           0.23/variant                                0.16/variant                         \<0.001
  Silent mutation number                            32/tumor                                   81.3/tumor                          0.03
  Mutation frequency (silent)                     0.23/variant                                0.14/variant                         \<0.001
  Putative driver mutation number                  2.8/tumor                                   10.6/tumor                          0.0002
  Representative driver mutation           *PIK3CA*, *FBXW7*, *BRCA2*   *FBXW7*, *BRCA2*, *TP53*, *HRAS*, *FAT1*, *APC*, *CDKN2A*  ---
                                                                                                                                    
  No. of CNAs                                  238 (median: 22.0)                          352 (median: 10.m)                      0.53
  Length of CNAs (Mb)                        2430.0 (median: 193.1)                       2495.4 (median: 96.4)                    0.75
  Most recurrent copy gain                             3q                                        7p, 8q                            ---
  Most recurrent copy loss                            11q                                          2q                              ---
  Kataegis                                      Positive (*n*=2)                            Negative (*n*=0)                        

Abbreviation: CNAs, copy number alterations.

###### Recurrently altered regions in vulvar SCCs by HPV status

  *HPV status*   *Event*    *Chr*        *Map position*         *Size*      *Cytoband*     *Freq*  *Cancer-related genes*
  -------------- --------- ------- -------------------------- ---------- ---------------- -------- --------------------------------------------------------------------------------------------------
  HPV (**+)**    CN Gain      1     144 214 303--144 596 037    381734        q21.1         50%     
                 CN Gain      3     118 644 873--159 947 520   41302647   q13.32--q25.33    67%    *GATA2*, *RPN1*, *CNBP*, *FOXL2*, *ATR*, *WWTR1*, *GMPS*, *MLF1*
                 CN Gain      3     160 282 987--198 022 430   37739443    q25.33--q29      83%    *MECOM*, *TBL1XR1*, *PIK3CA*, *SOX2*, *MAP3K13*, *ETV5*, *EIF4A2*, *BCL6*, *LPP*, *TP63*, *TFRC*
                 CN Gain      5       140 372--23 884 365      23743993   p15.33--p14.2     50%    *SDHA*, *TERT*
                 CN Gain      5      31 552 901--34 688 160    3135259     p13.3--p13.2     50%     
                 CN Loss     11      96 124 552--99 487 602    3363050      q21--q22.1      50%     
                 CN Loss     11     101 762 008--103 349 792   1587784     q22.1--q22.3     50%    *BIRC3*
                 CN Gain     13     100 336 156--101 714 451   1378295     q32.3--q33.1     50%     
                 CN Gain     18      2 796 420--17 200 000     14403580   p11.32--q11.1     67%     
                 CN Gain     18      18 517 121--34 840 647    16323526    q11.1--q12.2     50%    *ZNF521*, *SS18*
                 CN Gain     18      43 422 074--45 567 137    2145063     q12.3--q21.1     50%    *SMAD2*
                 CN Gain     18      46 645 092--47 957 549    1312457        q21.1         50%     
                 CN Gain     18      51 690 882--67 872 291    16181409    q21.2--q22.2     50%    *MALT1*, *BCL2*, *KDSR*
                 CN Gain     20      3 847 585--21 402 481     17554896    p13--p11.22      50%     
                 CN Gain     20      47 465 498--58 744 996    11279498   q13.13--q13.33    50%    *NFATC2*, *SALL4*, *GNAS*
  HPV (−)        CN Loss      2       3 698 900--3 698 947        47          p25.3         43%     
                 CN Loss      2     192 746 283--196 581 520   3835237        q32.3         57%     
                 CN Loss      2     202 625 760--203 620 248    994488     q33.1--q33.2     43%     
                 CN Loss      3      49 949 001--50 191 322     242321        p21.31        43%     
                 CN Loss      3      50 683 675--50 816 138     132463        p21.2         43%     
                 CN Loss      3      51 497 186--51 696 851     199665        p21.2         43%     
                 CN Loss      3      81 792 616--87 027 712    5235096     p12.2--p12.1     43%     
                 CN Loss      4     187 630 720--189 660 328   2029608        q35.2         43%    *FAT1*
                 CN Gain      7        766 289--2 771 308      2005019        p22.3         43%     
                 CN Gain      7       5 256 327--5 692 158      435831        p22.1         43%     
                 CN Gain      7      16 131 179--48 567 889    32436710    p21.2--p12.3     57%    *HNRNPA2B1*, *HOXA9*, *HOXA11*, *HOXA13*, *JAZF1*, *SFRP4*
                 CN Gain      8     141 542 615--142 489 103    946488        q24.3         57%     
                 CN Gain      8     145 918 761--146 364 022    445261        q24.3         43%     
                 CN Loss     10      99 426 796--99 473 736     46940         q24.2         43%     
                 CN Gain     14      22 386 737--23 012 133     625396        q11.2         43%     
                 CN Loss     21         5305--13 200 000       13194695     p13--q11.1      43%     
                 CN Loss      X           0--2 616 478         2616478        p22.33        43%    *CRLF2*, *P2RY8*
                 CN Loss      X      61 686 735--62 569 812     883077        q11.1         43%     

Abbreviations: CN gain, copy number gain; CN loss, copy number loss; Freq, frequency.

CNAs occurring in more than 40% of samples were defined as recurrently altered regions.

Cancer-related genes were extracted from the Cancer Gene Census (<http://cancer.sanger.ac.uk/census>) and genes previously reported in vulvar SCCs.^[@bib1],\ [@bib2],\ [@bib5],\ [@bib13],\ [@bib14],\ [@bib15]^
